Solana Leads Way As Most Big Cryptocurrencies Post Gains
This article was automatically generated by MarketWatch using technology from Automated Insights.
Most large cryptocurrencies were up during morning trading on Monday, with Solana seeing the biggest move, climbing 6.53% to $190.64.
Seven additional currencies posted raises Monday. Bitcoin climbed 2.88% to $68,055.80, and Ethereum increased 2.13% to $3,485.99.
Polygon climbed 1.98% to $1.03, while Polkadot increased 1.84% to $9.48. Cardano increased 1.20% to 65 cents.
Uniswap and Ripple rounded out the increases for Monday, with gains of 1.20% to $12.13 and 0.25% to 63 cents, respectively.
On the other hand, Dogecoin posted the only drop, falling 1.17% to 17 cents.
In crypto-related company news, shares of Coinbase Global Inc. rose 6.64% to $272.47, while MicroStrategy Inc. jumped 10.70% to $1,686.00. Riot Platforms Inc. shares rose 6.40% to $12.13, and shares of Marathon Digital Holdings Inc. rose 6.28% to $22.18.
Block Inc. climbed 0.52% to $81.19 and Tesla Inc. rose 0.96% to $172.47.
PayPal Holdings Inc. rose 1.45% to $65.71, and Ebang International Holdings Inc. shares increased 5.85% to $9.39. NVIDIA Corp. increased 1.26% to $954.79, and Advanced Micro Devices Inc. shed 1.56% to $176.86.
In the fund space, the Bitwise Crypto Industry Innovators ETF, which is focused on pure-play crypto companies, rose 5.43% to $13.02. Blockchain-focused Amplify Transformational Data Sharing ETF climbed 2.87% to $35.88.
Data source: Dow Jones Market Data, FactSet.
(END) Dow Jones Newswires
March 25, 2024 10:15 ET (14:15 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Markets Brief: AI Leaders Excel in Earnings Season
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth